Every step is a struggle for Bruce Zimmerman, whose health has been deteriorating since he was diagnosed with multiple sclerosis eight years ago. In 2019, Zimmerman said, his then-employer offered him an opportunity that sounded irresistible: He and his wife, Becky, could take all-expense-paid trips to the Cayman Islands and the …
Wall Street is barreling toward a big week ahead with Big Tech earnings, a critical Federal Reserve meeting and an important meeting between President Donald Trump and Chinese President Xi Jinping that could set the tone for the rest of the year. Stocks are on pace to wrap up a …
Check out the companies making the biggest moves midday: Generac — The generator company gained 8% after Bank of America raised its price target on the stock, highlighting the company’s entry into data centers . Baxter International — Shares fell around 20% after the health-care company reported weaker-than-expected results for …
Medications are stored on shelves at a pharmacy on May 12, 2025 in Los Angeles, California. Eric Thayer | Getty Images President Donald Trump is slated to impose tariffs on pharmaceuticals imported into the U.S. any day now – and the duties may have a bigger impact on some drugmakers …
Long-standing trade agreements have largely sheltered the pharmaceutical industry from tariffs but President Donald Trump’s goal of bringing manufacturing back to the United States has put the industry in the administration’s crosshairs. Trump first floated the idea of imposing tariffs of as much as 25% on imported pharmaceuticals in mid-February. …
Trends may be shifting in favor of biotech stocks in 2025 after several years of poor performance, but it would still be wise to place your bets carefully on some of the most innovative names. “We’re still optimistic on the outlook for biotech,” said Stacey Sears, senior vice president and …
Here are Monday’s biggest calls on Wall Street: Bank of America downgrades Advanced Micro Devices to neutral from buy Bank of America said it’s concerned about market share gain potential slowing. “Higher competitive risks in AI against best-of-breed NVDA’s dominance, and growing cloud preference for custom chips from MRVL/AVGO, limiting …
Hannah Yoon | The Washington Post | Getty Images Leqembi, an Alzheimer’s drug from Biogen and Eisai, isn’t a cure for the mind-damaging disease. But the treatment promises to give patients such as Missie Meeks more time to live their daily lives normally and independently of others. Meeks, an English …
GE Healthcare on Wednesday morning reported a mixed second quarter and shares initially moved sharply lower. The stock then reversed higher as the post-earnings call got underway. Management made it clear that they think that weakness in China is temporary and see many other levers available to grow earnings. Revenue …
As investors peer into the future to envision which industries are ripe to be reshaped and energized by artificial intelligence, drug discovery is fast emerging as an obvious choice. Each new drug that hits the market is the product of billions of dollars in investment, often taking at least a …